H.C. Wainwright analyst Yi Chen reiterated a Hold rating on CareDx (CDNA – Research Report) today and set a price target of $25.00.
Yi Chen’s rating is based on a combination of factors that reflect both positive growth and ongoing challenges for CareDx. The company reported a 17.5% year-over-year increase in total revenue for the first quarter of 2025, surpassing expectations. This growth was driven by a rise in testing services and product revenues, indicating a strong market presence. However, despite this positive performance, CareDx reported a net loss, albeit smaller than anticipated, which suggests ongoing financial challenges.
Additionally, while the management has reaffirmed its revenue guidance for 2025 and outlined key growth strategies, including new product launches and operational improvements, there remain uncertainties in the broader market environment. The company’s strong cash position provides a buffer, but the need for continued investment and restructuring efforts indicates that there are still hurdles to overcome. Thus, the Hold rating reflects a balanced view of the company’s current achievements and the potential risks ahead.
Chen covers the Healthcare sector, focusing on stocks such as Opko Health, OKYO Pharma Limited Sponsored ADR, and Vivani Medical. According to TipRanks, Chen has an average return of -15.2% and a 30.14% success rate on recommended stocks.
In another report released on May 2, Wells Fargo also maintained a Hold rating on the stock with a $19.00 price target.